Oxidized mannan-MOG35-55 conjugate as a basis for targeted immune modulation in multiple sclerosis

1

Multiple sclerosis (MS) is characterized by autoreactive T-cell responses against myelin antigens, leading to CNS inflammation and neurological disability.
2

Current disease-modifying therapies (DMTs) broadly suppress immune activity but do not restore antigen-specific immune tolerance and may cause adverse effects.
3

Oxidized mannan-conjugated myelin oligodendrocyte glycoprotein peptide (OM-MOG35-55) shows promise in modulating antigen-specific immune responses in MS.
4

OM-MOG35-55 enhances dendritic cell-mediated antigen presentation and promotes regulatory T-cell expansion and cytokine production.
5

The effectiveness of OM-MOG35-55 varies based on the antigen type and host genetic background, highlighting the need for personalized therapeutic strategies.

1